Cytokinetics Moves Closer to Second Approval with Aficamten
By Editor • August 28, 2026 • 1 min read
Cytokinetics is on the brink of securing its second regulatory approval with aficamten, targeting non-obstructive hypertrophic cardiomyopathy. The pivotal study released Friday revealed improvements in patient well-being and exercise ability.
The biotech firm aims to submit its application to the FDA by year-end, potentially making it the first approved treatment for nHCM.
Source: www.statnews.com
